NextCure (NASDAQ:NXTC) PT Raised to $44.00 at Bank of America

Share on StockTwits

NextCure (NASDAQ:NXTC) had its price target raised by Bank of America from $27.00 to $44.00 in a report released on Monday, BenzingaRatingsTable reports. Bank of America currently has a buy rating on the stock.

A number of other equities analysts have also recently commented on the company. Piper Jaffray Companies lifted their price target on NextCure from $26.00 to $54.00 and gave the stock an overweight rating in a research note on Thursday, September 5th. Morgan Stanley lifted their price target on NextCure from $25.00 to $33.00 and gave the stock an overweight rating in a research note on Tuesday, August 13th. Finally, Zacks Investment Research cut NextCure from a hold rating to a sell rating in a research note on Thursday, September 5th.

Shares of NASDAQ NXTC opened at $37.68 on Monday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 17.05 and a current ratio of 17.05. NextCure has a 1-year low of $13.86 and a 1-year high of $44.69. The firm’s 50-day moving average price is $27.84.

NextCure (NASDAQ:NXTC) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.61) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.15). The company had revenue of $1.40 million during the quarter, compared to the consensus estimate of $1.50 million. As a group, equities analysts expect that NextCure will post -1.89 earnings per share for the current year.

Institutional investors have recently made changes to their positions in the business. Victory Capital Management Inc. purchased a new position in NextCure in the 2nd quarter worth approximately $48,000. Tower Research Capital LLC TRC purchased a new position in NextCure in the 2nd quarter worth approximately $96,000. Morgan Stanley purchased a new position in NextCure in the 2nd quarter worth approximately $101,000. Northern Trust Corp purchased a new position in NextCure in the 2nd quarter worth approximately $337,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in NextCure in the 2nd quarter worth approximately $386,000. 47.47% of the stock is currently owned by institutional investors and hedge funds.

About NextCure

There is no company description available for NextCure Inc

See Also: What is a trade deficit?

Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.